22 results on '"Chow, Warren A."'
Search Results
2. Faculty Opinions recommendation of Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort.
3. Faculty Opinions recommendation of Efficacy and safety of TRC105 plus pazopanib vs pazopanib alone for treatment of patients with advanced angiosarcoma: A randomized clinical trial.
4. Faculty Opinions recommendation of Phase 1 study of combination pexidartinib and sirolimus to target tumor associated macrophages in unresectable sarcoma and malignant peripheral nerve sheath tumors.
5. Faculty Opinions recommendation of Therapeutic potential of NTRK3 inhibition in desmoplastic small round cell tumor.
6. Faculty Opinions recommendation of Negative MAPK-ERK regulation sustains CIC-DUX4 oncoprotein expression in undifferentiated sarcoma.
7. Faculty Opinions recommendation of B cells are associated with survival and immunotherapy response in sarcoma.
8. Faculty Opinions recommendation of Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma.
9. Faculty Opinions recommendation of Disulfiram reduces metastatic osteosarcoma tumor burden in an immunocompetent Balb/c or-thotopic mouse model.
10. Faculty Opinions recommendation of Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials.
11. Faculty Opinions recommendation of Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas.
12. Faculty Opinions recommendation of The complexity of integrins in cancer and new scopes for therapeutic targeting.
13. Faculty Opinions recommendation of Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
14. Faculty Opinions recommendation of Hedgehog signaling: from basic biology to cancer therapy.
15. Faculty Opinions recommendation of miR-181a Targets RGS16 to Promote Chondrosarcoma Growth, Angiogenesis, and Metastasis.
16. Faculty Opinions recommendation of Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays.
17. Faculty Opinions recommendation of Association of SOX4 regulated by tumor suppressor miR-30a with poor prognosis in low-grade chondrosarcoma.
18. Faculty Opinions recommendation of Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.
19. Faculty Opinions recommendation of First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
20. Faculty Opinions recommendation of IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas.
21. Faculty Opinions recommendation of Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.
22. Faculty Opinions recommendation of Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.